Arutha Kulasinghe1,2, Touraj Taheri3,4, Ken O'Byrne1,2,5, Brett G M Hughes4,6, Liz Kenny4,6, Chamindie Punyadeera1,2. 1. The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD, Australia. 2. Translational Research Institute, Brisbane, QLD, Australia. 3. Department of Pathology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia. 4. Royal Brisbane and Women's Hospital, Herston, QLD, Australia. 5. Princess Alexandra Hospital, Woolloongabba, QLD, Australia. 6. School of Medicine, University of Queensland, Brisbane, QLD, Australia.
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) patients. To identify patient-responders from non-responders, biomarkers are needed which are predictive of outcome to ICI therapy. Cues in the tumor microenvironment (TME) have been informative in understanding the tumor-immune contexture. METHODS: In this preliminary study, the NanoString GeoMx™ Digital Spatial Profiling (DSP) technology was used to determine the immune marker and compartment specific measurements in a cohort of HNSCC tumors from patients receiving ICI therapy. RESULTS: Our data revealed that markers involved with immune cell infiltration (CD8 T-cells) were not predictive of outcome to ICI therapy. Rather, a number of immune cell types and protein markers (CD4, CD68, CD45, CD44, CD66b) were found to correlate with progressive disease. Cross platform comparison with the Opal Vectra (Perkin Elmer) for a number of markers across similar regions of interest demonstrated concordance for pan-cytokeratin, CD8, and PD-L1. CONCLUSION: This study, to our knowledge, represents the first digital spatial analysis of HNSCC tumors. A larger cohort of HNSCC will be required to orthogonally validate the findings.
BACKGROUND: Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) patients. To identify patient-responders from non-responders, biomarkers are needed which are predictive of outcome to ICI therapy. Cues in the tumor microenvironment (TME) have been informative in understanding the tumor-immune contexture. METHODS: In this preliminary study, the NanoString GeoMx™ Digital Spatial Profiling (DSP) technology was used to determine the immune marker and compartment specific measurements in a cohort of HNSCC tumors from patients receiving ICI therapy. RESULTS: Our data revealed that markers involved with immune cell infiltration (CD8 T-cells) were not predictive of outcome to ICI therapy. Rather, a number of immune cell types and protein markers (CD4, CD68, CD45, CD44, CD66b) were found to correlate with progressive disease. Cross platform comparison with the Opal Vectra (Perkin Elmer) for a number of markers across similar regions of interest demonstrated concordance for pan-cytokeratin, CD8, and PD-L1. CONCLUSION: This study, to our knowledge, represents the first digital spatial analysis of HNSCC tumors. A larger cohort of HNSCC will be required to orthogonally validate the findings.
Authors: Ezra E W Cohen; Denis Soulières; Christophe Le Tourneau; José Dinis; Lisa Licitra; Myung-Ju Ahn; Ainara Soria; Jean-Pascal Machiels; Nicolas Mach; Ranee Mehra; Barbara Burtness; Pingye Zhang; Jonathan Cheng; Ramona F Swaby; Kevin J Harrington Journal: Lancet Date: 2018-11-30 Impact factor: 79.321
Authors: Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel Journal: Nat Med Date: 2018-04-23 Impact factor: 53.440
Authors: Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders Journal: Clin Cancer Res Date: 2014-04-08 Impact factor: 12.531
Authors: Henrique Lemos; Eslam Mohamed; Lei Huang; Rong Ou; Gabriela Pacholczyk; Ali S Arbab; David Munn; Andrew L Mellor Journal: Cancer Res Date: 2016-03-10 Impact factor: 12.701
Authors: Barbara Burtness; Kevin J Harrington; Richard Greil; Denis Soulières; Makoto Tahara; Gilberto de Castro; Amanda Psyrri; Neus Basté; Prakash Neupane; Åse Bratland; Thorsten Fuereder; Brett G M Hughes; Ricard Mesía; Nuttapong Ngamphaiboon; Tamara Rordorf; Wan Zamaniah Wan Ishak; Ruey-Long Hong; René González Mendoza; Ananya Roy; Yayan Zhang; Burak Gumuscu; Jonathan D Cheng; Fan Jin; Danny Rischin Journal: Lancet Date: 2019-11-01 Impact factor: 79.321
Authors: Isabelle Le Mercier; Wenna Chen; Janet L Lines; Maria Day; Jiannan Li; Petra Sergent; Randolph J Noelle; Li Wang Journal: Cancer Res Date: 2014-04-01 Impact factor: 12.701
Authors: Giacomo Miserocchi; Chiara Spadazzi; Sebastiano Calpona; Francesco De Rosa; Alice Usai; Alessandro De Vita; Chiara Liverani; Claudia Cocchi; Silvia Vanni; Chiara Calabrese; Massimo Bassi; Giovanni De Luca; Giuseppe Meccariello; Toni Ibrahim; Marco Schiavone; Laura Mercatali Journal: J Pers Med Date: 2022-05-24
Authors: Habib Sadeghirad; James Monkman; Ahmed M Mehdi; Rahul Ladwa; Ken O'Byrne; Brett G M Hughes; Arutha Kulasinghe Journal: Front Immunol Date: 2022-05-16 Impact factor: 8.786
Authors: Maurice van Duijvenvoorde; Sarah Derks; Idris Bahce; C René Leemans; Rieneke van de Ven; Marieke F Fransen Journal: Clin Transl Immunology Date: 2022-01-10
Authors: Christian Idel; Julika Ribbat-Idel; Luise Klapper; Rosemarie Krupar; Karl-Ludwig Bruchhage; Eva Dreyer; Dirk Rades; Christina Polasky; Anne Offermann; Jutta Kirfel; Sven Perner; Barbara Wollenberg Journal: Front Oncol Date: 2021-10-28 Impact factor: 6.244